Literature DB >> 19705123

Successful treatment with adalimumab in a patient with coexisting Behçet's disease and ankylosing spondylitis.

Necmettin Yildiz1, Hakan Alkan, Fusun Ardic, Oya Topuz.   

Abstract

The objective is to report a patient with concomitant ankylosing spondylitis (AS) and Behçet's disease (BD) successfully treated with adalimumab. A 44-year-old male diagnosed as AS applied to our outpatient clinic with complaints of morning stiffness, pain and limitation of motion at spine, concurrence of oral and genital ulcerated lesions. He was on sulfasalazine together with different NSAIDs for the past 1 year. According to the criteria of International Study Group, he was diagnosed as BD. The patient was considered as refractory to current treatment and adalimumab treatment was started. During follow-up, not only AS was in remission, but also no new oral and genital ulcerations appeared. There were no complications related to the use of anti-TNFalpha therapy. In our case it was observed that anti-TNFalpha therapy, specifically adalimumab, was effective for symptoms of both AS and BD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19705123     DOI: 10.1007/s00296-009-1104-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  23 in total

1.  Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy.

Authors:  P H Goossens; R J Verburg; F C Breedveld
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  Adalimumab: a new modality for Behçet's disease?

Authors:  J A M van Laar; T Missotten; P L A van Daele; A Jamnitski; G S Baarsma; P M van Hagen
Journal:  Ann Rheum Dis       Date:  2006-11-23       Impact factor: 19.103

3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

Authors:  D E Furst; E C Keystone; B Kirkham; A Kavanaugh; R Fleischmann; P Mease; F C Breedveld; J S Smolen; J R Kalden; G R Burmester; J Braun; P Emery; K Winthrop; B Bresnihan; F De Benedetti; T Dörner; A Gibofsky; M H Schiff; J Sieper; N Singer; P L C M Van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2008-12       Impact factor: 19.103

4.  Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy.

Authors:  D McGonagle; W Gibbon; P O'Connor; M Green; C Pease; P Emery
Journal:  Arthritis Rheum       Date:  1998-04

5.  Behçet syndrome with ankylosing spondylitis.

Authors:  M H Kallel; I Bejia; B Fournié; A Fournié
Journal:  Rev Rhum Engl Ed       Date:  1995-04

6.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

Review 7.  The sacroiliac joint in the spondyloarthropathies.

Authors:  J Braun; J Sieper
Journal:  Curr Opin Rheumatol       Date:  1996-07       Impact factor: 5.006

8.  Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

Authors:  Melike Melikoglu; Izzet Fresko; Cem Mat; Yilmaz Ozyazgan; Feride Gogus; Sebahattin Yurdakul; Vedat Hamuryudan; Hasan Yazici
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

Review 9.  Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature.

Authors:  G Almoznino; E Ben-Chetrit
Journal:  Clin Exp Rheumatol       Date:  2007 Jul-Aug       Impact factor: 4.473

10.  A change in ocular involvement in a patient suffering from ankylosing spondylitis and Behçet's disease.

Authors:  I Beiran; J Scharf; D Dori; B Miller
Journal:  Eur J Ophthalmol       Date:  1995 Jul-Sep       Impact factor: 1.922

View more
  1 in total

Review 1.  Coexisting Behçet's disease and ankylosing spondylitis presented with deep venous thrombosis: a case report and review of the literature.

Authors:  Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2010-03-30       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.